News Summary
PositiveEli Lilly delivered exceptional execution with 48% Q2 revenue growth, raised full-year 2026 guidance to $85–$87B, and secured FDA approval for Foundayo (first GLP-1 oral pill with no food/water restrictions) plus positive Phase 3 data for retatrutide (triple hormone agonist). However, HSBC's March downgrade flagged consensus may be overestimating the GLP-1 obesity market size by $30–70B, posing potential long-term headwind despite near-term momentum.
Red flags
- •HSBC analyst downgrade on GLP-1 market size consensus—projects $80–120B by 2032 vs. Wall Street's $150B+, suggesting market may be overpriced into estimates
- •Heavy reliance on GLP-1 franchise for revenue growth; obesity drug market competition intensifying (Novo Nordisk, others)
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Glenview Capital | Larry Robbins | 58K | +58K | $69M | 1.4% | — | NEW |
| Duquesne Family Office | Stanley Druckenmiller | 12K | +12K | $15M | 0.3% | — | NEW |
| Point72 | Steve Cohen | 10K | +10K | $13M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where LLY ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #21 of this fund's book
- 18DICKS SPORTING GOODS INC$91M
- 19GENIUS SPORTS LIMITED$82M
- 20ONTO INNOVATION INC$78M
- 21ELI LILLY & CO$69M
- 22UNITED AIRLS HLDGS INC$67M
- 23NATIONAL VISION HLDGS INC$59M
- 24CISCO SYS INC$49M
Values are quarter-end position sizes. Shown only for funds where LLY ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| LILLY ENDOWMENT, INC. | SC 13G/A | 90.4M | 9.6% | 2026-07-23 | ↗ |
| Vanguard Capital Management | SC 13G | 61.3M | 6.5% | 2026-05-01 | ↗ |
| LILLY ENDOWMENT, INC. | SC 13G/A | 91.9M | 9.7% | 2026-04-20 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Gilbert Cisneros | house | CA31 | BUY | $50,001 - $100,000 | 2026-06-10 | 2026-07-02 | ↗ |
| Alan Armstrong | senate | — | SELL | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
| Thomas H Tuberville | senate | — | SELL | $15,001 - $50,000 | 2025-04-15 | 2026-08-05 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures.